Methyl aminolevulinate - Photocure

Drug Profile

Methyl aminolevulinate - Photocure

Alternative Names: 5-ALA methylester; 5-ALA-methylesther; Aminolevulinic acid methyl ester; Luxerm; MAL-PDT; Methyl 5 aminolevulinate; Methylaminolevulinate; Metvix; Metvix Natural Daylight Photodynamic Therapy - Galderma; Metvix NDL-PDT; Metvix PDT; Metvixia; P 1202; Visonac

Latest Information Update: 31 Jul 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Norwegian Radium Hospital; PhotoCure
  • Developer Galderma; Healthcare Logistics; Photocure
  • Class Amino acids; Antineoplastics; Levulinic acids; Oxidants; Skin disorder therapies; Small molecules
  • Mechanism of Action Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Actinic keratosis; Basal cell cancer; Squamous cell cancer
  • Phase II Acne
  • Discontinued Skin aging

Most Recent Events

  • 31 Jul 2017 Discontinued - Phase-II for Skin aging in United Kingdom (Topical)
  • 01 Mar 2017 Galderma completes a phase II trial for Actinic keratosis in Denmark (Topical) (NCT03006185)
  • 09 Apr 2015 The product is approved for Actinic keratosis and Basal cell cancer in Mexico and is in phase-II development for Acne in USA, Canadd and Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top